Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research

Peregrine Pharmaceuticals cuts 20% of workforce to reduce costs

PBR Staff Writer Published 14 August 2017

Peregrine Pharmaceuticals has cut down its workforce by up to 20%, as part of its efforts to decrease costs and achieve overall profitability.

The company has laid off 60 employees under the planned strategic actions, as well as pursuing strategic options for its research and development (R&D) assets.

The reduction in employees is expected to help Peregrine to have net cost savings between $3.7m and $4.3m in fiscal year 2018. It will also allow to reduce annualized operating expenses starting in fiscal year 2019.

Peregrine has reduced its R&D personnel by 50% to 11 employees, as part of the cost saving initiatives.

Personnel supporting Peregrine’s wholly-owned subsidiary Avid Bioservices’ contract development and manufacturing organization (CDMO) business has been decreased by 20% to 184 employees to coordinate operations.

The company has reduced selling, general and administrative (SG&A) personnel by % to 49 employees to pursue leaner support operations. These measured are expected to save between $1.1m and $1.7m during the second quarter of fiscal year 2018.

Peregrine president, CEO and director Steven King said: "I would like to personally express my appreciation to the affected employees for their commitment and meaningful contributions to the Peregrine and Avid businesses.

“We remain committed to capitalizing on long-term opportunities available to our CDMO business and pursuing the best path forward for our R&D business."

Peregrine offers CDMO services, including cGMP manufacturing and development capabilities, for the development of pharmaceutical products.

The firm is also working to assess its immunotherapy candidate bavituximab in combination with immune stimulating therapies to treat various cancers and developing its advanced exosome technology for the detection and monitoring of cancer.

Avid Bioservices offers a range of process development, cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Its services comprised of cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support.


Image: Peregrine provides CDMO services for the development of pharmaceutical products. Photo: courtesy of jk1991 / FreeDigitalPhotos.net.